ClinicalTrials.gg
CompletedNCT02031224KETOPROGUpdated Dec 22, 2017

Supplemented Very Low Protein Diet and the Progression of Chronic Kidney Disease

A Phase 4 interventional study of Conventional low protein diet and Very low protein diet supplemented with Ketosteril in Chronic Kidney Disease, sponsored by Anemia Working Group Romania. Completed at 1 site in Romania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Anemia Working Group Romania · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.

Enrollment
35th of 56
250 · median 455
Started
2008
with 4 others
Phase 4
4 of 65
1 open now
Registered
29th of 65
by date
Lead sponsor
4 of 65
Anemia Working Group Romania

Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is the 35th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2008, is one of 4 in phase 4, and was the 29th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Renal Insufficiency, Chronic with a site in Romania, or all of them as a file.
02

Study summary

This is a prospective single center randomized controlled trial with a total duration of 18 months aiming to evaluate the effectiveness and the safety of a very low protein diet supplemented with ketoanalogues of essential aminoacids in reducing the progression of chronic kidney disease (CKD) in patients with advanced CKD.

Read the detailed description

All eligible patients who will give informed consent will be screened. Those meeting the selection criteria will be enrolled and will enter a 3-month run-in phase during which a conventional LPD will be prescribed in all patients.

At the end of this phase, the subjects still fulfilling all the selection criteria will be randomized in a 1:1 ratio to receive the KD or to continue the conventional LPD for a total duration of 15 months.

Nineteen blood and urine samplings are scheduled for each patient, to be drawn monthly. The laboratory reports include the nitrogen compounds, calcium-phosphorus metabolism parameters, acid-base balance, biochemical nutritional markers, serum C-reactive protein, hemoglobin, blood cell count, and biochemical safety parameters (sodium, potassium, liver enzymes, and bilirubin).

The anthropometric measurements and subjective global assessment will be evaluated at enrolment, at randomization, and every 3 months thereafter.

The compliance with the prescribed diet (protein and energy intake) will be assessed monthly during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and every 3 months thereafter.

The blood pressure levels, drugs required for the therapy of hypertension, acidosis and mineral metabolism disorders, and occurrence of adverse events will be recorded monthly.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Chronic Kidney Disease
  • Restricted protein diets
  • Nutritional status
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult non-diabetic patients
  • stage 4-5 CKD not on dialysis (estimated glomerular filtration by Modification of Diet in Renal Disease formula \< 30 mL/min per year
  • stable renal function at least 12 weeks before enrollment
  • well-controlled arterial blood pressure
  • proteinuria less than 1 g/g urinary creatinine
  • good nutritional status
  • declared and anticipated good compliance with the prescribed diet

Exclusion criteria

Exclusion Criteria:

  • poorly controlled arterial blood pressure (≥145/85 mm Hg)
  • relevant comorbid conditions (diabetes mellitus, heart failure, active hepatic disease, digestive diseases with malabsorption, inflammation/anti-inflammatory therapy)
  • uremic complications (pericarditis, polyneuropathy)
  • feeding inability (anorexia, nausea)
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Keto-diet (KD)

    Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.

    Dietary Supplement: Very low protein diet supplemented with Ketosteril

  • Active comparator
    Low Protein Diet group (LPD)

    The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins). The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms.

    Behavioral: Conventional low protein diet

Interventions

  • BehavioralConventional low protein diet

    Also known as: LPD, Hypoproteic diet

  • Dietary supplementVery low protein diet supplemented with Ketosteril

    Also known as: SVLPD, Keto-diet

06

What researchers measure

Primary outcomes

  1. Primary composite endpoint

    Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate compared to randomization

    Time frame: 15 months after randomization

Secondary outcomes

  1. Secondary efficacy parameter

    The rate of decline in the estimated Glomerular Filtration Rate

    Time frame: months 3-15 after randomization

  2. Secondary outcome measure - nitrogen balance

    variations in serum urea

    Time frame: 15 months after randomization

  3. Secondary efficacy parameter - mineral metabolism

    variations in total serum calcium

    Time frame: 15 weeks after randomization

  4. Secondary efficacy parameter

    variations in serum phosphate level

    Time frame: 15 weeks after randomization

  5. Secondary efficacy parameter

    variations in serum bicarbonate

    Time frame: 15 weeks after randomization

  6. Secondary safety parameter

    Subjective Global Assessment of the nutritional status

    Time frame: 18 weeks after enrolment

  7. Secondary safety parameter

    Body Mass Index

    Time frame: 18 weeks after enrolment

  8. Secondary outcome measure - Nutritional status

    Tricipital skinfold

    Time frame: 18 weeks after enrolment

  9. Secondary safety parameter - anthropometric measures

    Mid-arm muscular circumference

    Time frame: 18 weeks after enrolment

  10. Nutritional status - biochemical markers

    serum albumin

    Time frame: 18 weeks after enrolment

  11. Inflammation

    serum level of C reactive protein

    Time frame: 18 weeks after enrolment

  12. Nutritional status - biochemical marker

    Serum total cholesterol

    Time frame: 18 weeks after enrolment

  13. Secondary safety parameter

    Serum potassium level

    Time frame: 18 weeks after enrolment

  14. Secondary safety parameter

    liver enzymes: Aspartate Aminotransferase, Alanine Transaminase

    Time frame: 18 weeks after enrolment

  15. Safety parameter - adverse events

    Occurrence of any adverse event

    Time frame: 18 weeks after enrolment

  16. Secondary safety parameter - withdrawals

    number of withdrawals

    Time frame: 18 weeks after enrolment

Other outcomes

  1. Compliance - protein intake

    urinary urea nitrogen excretion to calculate the protein intake

    Time frame: 18 months after enrolment

  2. Compliance - energy intake

    3-day food diary to calculate the daily energy intake

    Time frame: 18 weeks after enrolment

07

Study locations

1 site
  • "Dr Carol Davila" Teaching Hospital of Nephrology
    Bucharest, 010731, Romania
08

References and documents

Publications

  • Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007 May;17(3):179-88. doi: 10.1053/j.jrn.2006.12.012. PubMed 17462550 ↗
  • Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 29;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5. PubMed 33118160 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2014
First posted
Jan 9, 2014
Start
Mar 2008
Primary completionActual
Jun 2014
CompletionActual
Aug 2014
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02031224
Lead sponsor
Anemia Working Group Romania
Collaborators
Dr Carol Davila Teaching Hospital of Nephrology Bucharest
Responsible party
Liliana Garneata (Assistant Professor of Nephrology, MD, PhD, Carol Davila University of Medicine and Pharmacy) — Principal investigator
First posted
Jan 9, 2014
Start date
Mar 2008
Primary completion
Jun 2014
Completion
Aug 2014
Last update
Dec 22, 2017

Study contacts

Gabriel Mircescu, Prof
study chair · Carol Davila University of Medicine and Pharmacy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion